Clinical Trial Update: Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MK-3281 in Healthy and Hepatitis C Infected Male Participants (MK-3281-002) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating safety, tolerability, and pharmacokinetics of MK-3281 in healthy and hepatitis C infected male participants has completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• MK-3281

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Hepatitis C | Phase 1 | Status: COMPLETED | Results posted: 2016-05-04